Verastem Poised for Breakout with Imminent FDA Approval
AI Prediction of Verastem, Inc. (VSTM)
Verastem, a biopharmaceutical company, is on the cusp of potentially transformative growth with its focus on RAS/MAPK pathway-driven cancers. The upcoming catalysts, including the possible FDA approval of its leading drug candidates avutometinib and defactinib for low-grade serous ovarian cancer, could significantly impact its market valuation and operational dynamics. Considering the strategic alignment with industry requirements and the anticipation surrounding its clinical results, Verastem presents a compelling investment opportunity with considerable upside potential.
VSTM Report Information
Prediction Date2025-07-03
Close @ Prediction$4.80
Mkt Cap561m
IPO Date2012-01-27
AI-derived Information
Recent News for VSTM
- Mar 5, 8:30 am — Verastem, Inc. Q4 2025 Earnings Call Summary (Moby)
- Mar 5, 12:03 am — Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and ... (GuruFocus.com)
- Mar 4, 8:48 pm — Verastem Q4 Earnings Call Highlights (MarketBeat)
- Mar 4, 5:10 pm — Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
- Mar 4, 4:20 pm — Verastem: Q4 Earnings Snapshot (Associated Press Finance)
- Mar 4, 4:01 pm — Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
- Feb 18, 7:30 am — Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 (Business Wire)
- Feb 17, 12:00 pm — What Makes Verastem (VSTM) a New Buy Stock (Zacks)
- Feb 16, 1:02 am — Verastem Touts 50%+ Sales Growth for LGSOC Launch, Teases RAMP 301 and KRAS G12D Catalysts (MarketBeat)
- Feb 5, 11:42 am — Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks)
- Feb 4, 8:00 am — Here Are Wednesdays Top Wall Street Analyst Research Calls: AES Corp, Airbnb, Cloudflare, Devon Energy, Levi Strauss, Lumentum, PayPal, and More (24/7 Wall St.)
- Feb 4, 7:30 am — Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers (Business Wire)
NDAPR events for VSTM
-
Mar 9, 12:56 pmRevision: NO_CHANGE | Price Pressure Direction: NONE | Thesis Unchanged?: YES_UNCHANGEDRationale: No new catalysts or significant changes affecting the original prediction were identified.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.